FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. AMC
4. WBD
5. MSFT
6. ACN
7. FFAI
8. PAA
9. TLT
10. PAGP

Go back to FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Regeneron (NASDAQ: REGN) Delayed: 786.03 +1.18 (0.15%)
Previous Close $784.85    52 Week High $592.36 
Open $786.03    52 Week Low $325.35 
Day High $786.03    P/E 206.31 
Day Low $786.03    EPS $3.81 
Volume 5,897       

SANOFI (NASDAQ: SNY) Delayed: 42.48 --0 (-0%)
Previous Close $42.48    52 Week High $44.76 
Open $42.48    52 Week Low $36.81 
Day High $42.48    P/E N/A 
Day Low $42.48    EPS $0.00 
Volume 19,704